# Clinical Utility of Early vs. Late Blood Biomarker Testing for Alzheimer's Disease

> **NCT06856681** · NA · WITHDRAWN · sponsor: **C2N Diagnostics**

## Conditions studied

- Alzheimers Disease

## Interventions

- **DIAGNOSTIC_TEST:** PrecivityAD2 - Early Testing
- **DIAGNOSTIC_TEST:** PrecivityAD2 - Delayed Testing

## Key facts

- **NCT ID:** NCT06856681
- **Lead sponsor:** C2N Diagnostics
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-07
- **Primary completion:** 2027-12
- **Final completion:** 2028-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** sponsor decision to cancel project before enrollment.
- **Last updated:** 2025-12-16

## Collaborators

- Alzheimer's Association

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06856681

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06856681, "Clinical Utility of Early vs. Late Blood Biomarker Testing for Alzheimer's Disease". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06856681. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*